Tipifarnib in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia

Overview

Tipifarnib may stop the growth of cancer cells by blocking the enzymes necessary for their growth. Phase II trial to study the effectiveness of tipifarnib in treating older patients who have previously untreated acute myeloid leukemia

Full Title of Study: “A Phase II Study of Farnesyl Transferase Inhibitor R115777 (Zarnestra) (R115777 ( Zarnestra), Tipifarnib, R115777, NSC #702818) in Elderly Patients With Previously Untreated Poor-Risk Acute Myeloid Leukemia”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: July 2007

Detailed Description

PRIMARY OBJECTIVES: I. To determine the complete response rate of R115777 (tipifarnib) in previously untreated acute myeloid leukemia (AML) in (a) elderly patients (age >= 75) and (b) patients (age >= 65) with AML preceded by myelodysplastic syndrome (MDS), using a chronic dosing schedule. SECONDARY OBJECTIVES: I. To determine progression-free and overall survival in patients with previously untreated AML treated with R115777, using a chronic dosing schedule. II. To determine the duration of response in patients with previously untreated AML treated with R115777, using a chronic dosing schedule. III. To determine the effect of R115777 on the phosphorylation of mitogen-activated protein kinase (MAPK) and phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (PI3K) in leukemic cells. IV. To determine the effect of R115777 on processing of the farnesylated protein HDJ-2. V. To determine the toxicities of R115777 when given in a chronic dosing schedule. OUTLINE: This is a multicenter study. Patients receive oral tipifarnib twice daily on days 1-21. Patients with a complete or partial response, hematologic improvement, or stable disease continue treatment every 29-63 days in the absence of disease progression or unacceptable toxicity. Patients with a complete response after the second course of therapy receive 2 additional courses of therapy. Patients are followed for survival. PROJECTED ACCRUAL: A total of 125 patients will be accrued for this study within 11-17 months.

Interventions

  • Drug: tipifarnib
    • Given orally
  • Other: laboratory biomarker analysis
    • Correlative studies

Arms, Groups and Cohorts

  • Experimental: Treatment (tipifarnib)
    • Patients receive oral tipifarnib twice daily on days 1-21. Patients with a complete or partial response, hematologic improvement, or stable disease continue treatment every 29-63 days in the absence of disease progression or unacceptable toxicity. Patients with a complete response after the second course of therapy receive 2 additional courses of therapy.

Clinical Trial Outcome Measures

Primary Measures

  • Complete remission (CR) rate
    • Time Frame: Up to 8 years
    • CR rates will be calculated with 95% confidence intervals for each age group separately.

Secondary Measures

  • Partial remission (PR) rate
    • Time Frame: Up to 8 years
    • Will be estimated by observed proportions and 95% confidence intervals.
  • Toxicity rates assessed using NCI CTCAE version 3.0
    • Time Frame: Up to 8 years
    • Will be estimated by observed proportions and 95% confidence intervals.
  • Duration of response
    • Time Frame: From the time measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented, assessed up to 8 years
    • Duration of response and survival will be summarized by the Kaplan-Meier estimate of the survival distribution.
  • Duration of survival
    • Time Frame: From time of enrollment onto this study to the time of death, assessed up to 8 years
    • Duration of response and survival will be summarized by the Kaplan-Meier estimate of the survival distribution.

Participating in This Clinical Trial

Inclusion Criteria

  • Pathologic confirmation of the diagnosis of AML (>= 20% marrow blasts) – ECOG performance status 0 or 1 – Patients must be able to give informed consent – SGOT and SGPT =< 2.5 x normal limits (grade 1) – Serum creatinine =< 1.5 x normal limits (grade 1) – AML (any of the following): – Newly diagnosed AML in adults >= 75 years – Newly diagnosed AML arising from MDS in adults >= 65 years – Hyperleukocytosis with >= 30,000 leukemic blasts/uL Exclusion Criteria:

  • Acute promyelocytic (FAB M3) subtype – Previously treated with chemotherapy for leukemia (except for hydroxyurea) – Disseminated intravascular coagulation (laboratory or clinical) – Active central nervous system leukemia – Concomitant radiation therapy, chemotherapy, or immunotherapy; previous therapy for another malignancy is permitted, provided that at least 1 month has occurred since patient received any of these treatments – Intrinsic impaired organ function (as stated above) – Symptomatic neuropathy (grade 2 or worse) – Known allergy to imidazole drugs, such as ketoconazole, miconazole, econazole, teconazole, clotrimazole, fenticonazole, isoconazole, sulconazole, or ticonazole – Physical or psychiatric conditions that in the estimation of the principal investigator (PI) or designee place the patient at high risk of toxicity or non-compliance, e.g. severe congestive heart failure (CHF), unstable angina, or poorly controlled psychosis

Gender Eligibility: All

Minimum Age: 65 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • National Cancer Institute (NCI)
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Judith Karp, Principal Investigator, Johns Hopkins University

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.